Predictability


Fluofarma High Content Screening technology enables large-scale analysis of compounds in their real cellular environment. Thus, in contrast to standard drug discovery methods, Fluofarma's HCS technology is both powerful and highly predictive.

Our technology enables:
Functional measuring: Assessment of molecular events in living cells
Multiplexing analysis: Measure of up to 5 parameters simultaneously in single cells


Fluofarma's proprietary technology affords a highly predictive method for identifying, selecting, characterizing and understanding any kinds of compounds and its effects.  

Download Platform.pdf

Breaking news

  • Scientific Publication

    Fluofarma is glad to announce a new scientific publication in the journal Biochimica et Biophysica Acta - Molecular Cell Research.

    Read more [+]

  • IFSCC 2008

    Fluofarma will be attending IFSCC 2008, in Barcelona, from October 6th to 9th.

    Read more [+]

  • INVITOX 2008

    Fluofarma will be attending the INVITOX 2008 meeting, in Stockholm from September 25th to 28th.

    Read more [+]

  • EuroBio 2008

    Fluofarma will be attending EuroBio 2008, in Paris from October 7th to 9th.

    Read more [+]

  • SMi's Cell-Based Assays 2008

    Fluofarma will be attending SMi's Cell-Based Assays conference, in London from November 19th to 20th.

    Read more [+]

  • GDDI Forum 2009

    Fluofarma will be attending Global Discovery & Development Innovation Forum 2009, in London, from March 2nd to 3rd.

    Read more [+]

FOCUS: Anticancer drugs profiling
Fluofarma has developed DCffer® method, a powerful approach to compare and profile your anti-cancer drugs. Read more [+]